
Disclosure: Illumisoft is an Equity.Guru marketing client.
You know the old saying, “Sunlight is the best disinfectant?”
It’s not just a cute old saying. We’ve know for a long time that UV light, in hard enough concentrations and at the right part of the spectrum, can kill germs.
Here’s something we learned during COVID that, apparently, we’re determined to forget as quickly as possible: the air we breathe indoors can be a filthy, disease-carrying soup, and we’ve spent decades pretending that opening a window occasionally is an adequate response.
I don’t know about you, but if I leave my window open for the evening, the next day the window sill is covered in bus exhaust dust, and that’s just what I can immediately see. Lord knows what’s in the air when I stop into a cafe, or a bar, or a stadium, subway, hospital..
In Russia this month, a lab accident saw pneumonic plague hit the countryside. In the US, they’re chasing measles about from state to state. And in the middle of all that, I took a plane to Toronto this month and came back with the latest incarnation of COVID.
We disinfect our hands. We sterilize surgical equipment. We chlorinate drinking water. We inspect restaurant kitchens and shut down swimming pools if someone’s kid doesn’t make it to the restroom.
But the air that’s all around us?
We pack 200 people into a waiting room, classroom, airport lounge or hospital ward, have everyone breathe into the same enclosed space for eight hours, and hope for the best. Which is an interesting strategy when you consider that the next pandemic isn’t a question of if, but which one?
And the next one might not be so accommodating as COVID was.
Enter Illumisoft Lighting Corp (UVC.V), a Canadian electronics company that has decided there’s money to be made fixing a problem that governments, hospitals and building operators have spent an extraordinary amount of time discussing, and a considerably smaller amount of time actually solving.
Illumisoft isn’t a biotech company trying to invent a vaccine. It isn’t developing a new antibiotic, and it doesn’t need to convince anyone to swallow a pill. It makes lights.
You have lights. You like lights. How would you feel about switching them out for lights that kill pathogens?
More specifically, UVC makes commercial LED lighting systems and ultraviolet devices designed to kill or deactivate airborne pathogens before they get an opportunity to ruin someone’s week, or life.
Stick ’em in the lobby and go about your business. Put them in high traffic areas and eat a taco. The people being protected might not even realize it beyond the occasional thought of, ‘is it just me or does this lobby have a slight purplish hue..?’
No, this isn’t a concept seeking funding for testing. It’s not a product they’re hoping to get certified. It’s selling commercially, right now.
Unlike a lot of small-cap companies promising to revolutionize healthcare, Illumisoft actually has functioning technology, independent laboratory testing, regulatory registration and products being sold today. It’s not a hope, it’s the real deal.
Which doesn’t automatically make it a good investment, but it does make it worth a closer look.
So let’s look.
Killing bugs with light isn’t science fiction
Ultraviolet germicidal irradiation has been around for decades. UV-C light damages the genetic material of microorganisms, preventing them from reproducing or remaining infectious.
Hospitals have used versions of the technology for years. Water treatment facilities use it. Laboratories use it.
The problem has traditionally been getting enough UV exposure to kill airborne pathogens without exposing humans to dangerous radiation.
Illumisoft’s answer is a product called SaniLume, an upper-room UV-C disinfection system that uses 254-nanometre ultraviolet light and air circulation to treat airborne microorganisms.
The idea is straightforward. Air containing pathogens moves through the treated zone, UV-C damages the microorganisms, and the air returns to the occupied space with fewer viable pathogens.
You don’t need to evacuate the building or spray chemicals around the room, you don’t need a Hazmat suit, and you don’t need to wait for a pandemic to set in to make it useful.
Hospitals, aged-care facilities, schools, office buildings and transportation hubs are all potential customers – and some are actual customers – right now.
But here’s where things get interesting. In 2022, the University of Leeds conducted independent testing on Illumisoft’s SaniLume technology. The reported results included reductions of up to 99.7% for Pseudomonas aeruginosa and 99.2% for Staphylococcus aureus, two bacterial species associated with serious hospital infections.
The company’s investor presentation also reports equivalent air-change performance ranging from 201 to 1,994 total air changes per hour under its laboratory test conditions.
These are substantial numbers, tested by real scientific pointy heads.
Of course, before anyone starts ordering a thousand units for the summer cabin and declaring victory over infectious disease, a few qualifications.
The testing was conducted in a controlled chamber, not a functioning hospital full of moving people, open doors and unpredictable airflow. The viral testing used Phi-6 bacteriophage as a surrogate, rather than a live human pathogen. And a reduction in airborne microorganisms in a laboratory does not automatically translate into the same corresponding reduction in hospital-acquired infections. We haven’t yet fixed all of the world’s curses.
That said, this isn’t a PowerPoint presentation describing what might theoretically happen if somebody invented the right technology one day sometime. The device exists already. It has been tested. And SaniLume received Health Canada Pest Management Regulatory Agency registration in 2025.
That’s a considerably better starting point than most speculative medi-tech stories.
The hospital problem, by itself, is enormous
According to figures cited in Illumisoft’s investor presentation, Canada experiences approximately 473,590 healthcare-associated infections annually, with more than 33,000 deaths linked to those infections.
The presentation estimates an annual economic burden of $29.3 billion when treatment costs and lost hospital capacity are considered.
Those are figures from the Coalition for Community and Healthcare Acquired Infection Reduction, or CHAIR.
The underlying problem isn’t controversial. When patients are in hospital. they are obviously surrounded by other patients, visitors, and staff, each of whom may carry germs with them, either from being sick or being around people who are. The air they breathe can be more prone to infection causing pathogens than we realize.
And when immune suppressed patients get infections as a result, that costs money, occupes beds, complicates treatment and, in the worst case scenario, kills people. Globally, antibiotic resistance is making the situation worse.
The World Health Organization has warned repeatedly about antimicrobial resistance. Bacteria are becoming increasingly difficult to treat because of antibiotic overuse, and the development of new antibiotics isn’t keeping pace.
But antibiotic resistant pathogens aren’t inherently protected against germicidal UV-C light. And there’s a very compelling economic argument for preventing an infection rather than paying to treat one.
Illumisoft suggests an illustrative figure of approximately $20,000 in avoided treatment and hospital-capacity costs per single prevented infection. If a hospital can demonstrate that a relatively inexpensive air-treatment installation prevents even a modest number of infections, the financial case starts looking REALLY attractive.
The operative word, of course, is demonstrate. Because hospitals want evidence before they allocate budgets, approvals and accountability.
Which brings us to Illumisoft’s first major commercial test.
The 1,500-unit opportunity
Illumisoft says two hospital programs associated with CHAIR have budgeted for approximately 1,500 SaniLume units under a signed letter of intent, which is potentially significant.
For a company in the early stages of commerciability, a meaningful institutional deployment could change the financial picture considerably. Of course, a letter of intent is not necessarily a sales contract. And 1,500 proposed units are not 1,500 units shipped, installed and paid for.
If the program converts, Illumisoft could have an institutional reference customer that helps open doors elsewhere.
If it doesn’t, the company is left with a promising product and a very small revenue base.
Having more flexibility opens up all sorts of new commercial options, so Illumisoft is working on the next generation.
Enter: SaniLux
While SaniLume represents Illumisoft’s immediate commercial opportunity, the more ambitious technology is called SaniLux.
This is where the company moves into far-UVC, specifically a proposed 216-nanometre platform.
The appeal of far-UVC is that certain wavelengths may offer effective pathogen inactivation with different skin and eye exposure characteristics from conventional germicidal ultraviolet light.
In principle, that could expand the range of environments in which UV disinfection can operate safely while people are present. Think schools, aircraft, public transit, shopping centres, offices and hospitals.
Not just treating air in a designated upper-room zone, but potentially creating more flexible disinfection systems for occupied spaces.
Illumisoft says its objective is to deliver approximately ten times more far-UVC output per dollar than competing excimer-based approaches.
That’s an ambitious target, if they can pull it off.
The company has engaged the respected firm Capgemini for product engineering, industrial design, manufacturing readiness and commercialization planning, with an initial commercial target of the first quarter of 2027.
The investor presentation references 20 granted US patents, while earlier corporate disclosure references 17 patents associated with the acquired business, so one can see that research and development continues at a pace.
Patents can be enormously valuable – if they reach commercialization.
Illumisoft: The Pubco
Illumisoft completed its public-market qualifying transaction in April 2026, raising approximately $6.44 million at $0.30 per share. As of June 30, it had approximately $3.43 million in cash and 46.17 million shares outstanding.
The balance sheet is certainly stronger than it was before the financing. The company reported a net loss of approximately $2.71 million, including a substantial one-time listing expense of approximately $1.1 million, which is what you’d expect at an early stage.
Operating activities consumed approximately $1.82 million in cash over the six months, or around $303k a month.
At that historical spending rate, the June cash balance represented roughly eleven months of operating runway, assuming no meaningful changes to spending, revenue or financing.
Management attributes some of the weakness to resources being redirected toward the public listing, which is fair.
But the company also reported a small gross loss of approximately $158,000 in the first half of 2026.
That obviously isn’t sustainable indefinitely but it doesn’t present an impossible task to build from.
Obviously, valuing an emerging technology company solely on trailing sales can be misleading. A company developing technology for a potentially enormous market can be worth considerably more than its revenue suggests when you’re dealing with a small sample size of testing clients.
The company points to an estimated $9.7 billion hospital serviceable market for SaniLume, approximately $8 billion in North American LED retrofits and an initial $5.25 billion market opportunity for SaniLux, figures which illustrate the size of the potential opportunity, not the amount of business Illumisoft is entitled to capture.
A big market is useful. In its investor presentation, Illumisoft compares it’s valuation with a much higher private-market valuation for air-disinfection company R-Zero. That’s an interesting comparison, but what matters is whether Illumisoft can establish a repeatable sales process.
Admittedly, that’s a risk, but that’s also why you get the stock at the price its at today, and not 5x.
Like pathogens, the pandemic business is growing
Here’s the part of the story I find particularly compelling.
COVID didn’t invent airborne disease. It merely reminded everyone how quickly respiratory pathogens can overwhelm healthcare systems and disrupt economies. Influenza hasn’t disappeared in over century. Neither have measles outbreaks, tuberculosis, emerging zoonotic infections or the growing problem of antimicrobial-resistant bacteria.
Not all of those threats spread in the same way, and not all are equally suited to airborne disinfection. But there’s an unmistakable long-term case for improving indoor air quality and reducing exposure to airborne pathogens, regardless of what may be on the CDC’s newsfeed on a given day.
And the demand doesn’t have to depend on another global pandemic.
A hospital that reduces infections saves money every year.
A school that reduces airborne transmission potentially reduces absenteeism.
An airport that improves indoor air quality offers another layer of protection to thousands of travellers passing through shared spaces.
The challenge is convincing institutions to pay for prevention when the financial benefits can be difficult to measure and the budgets belong to different departments.
Hospitals understand the cost of treating an infection. Whether that understanding translates into purchasing thousands of UV disinfection devices is a separate question.
But building standards and infection-control expectations are evolving, and technologies that can demonstrate measurable benefits have a reason to exist. This is a market that could grow significantly even without another pandemic.
That said, being in this space at the moment when another major outbreak sharpens everyone’s focus on airborne infection control, is an investor’s dream.
That said, Illumisoft shouldn’t need a global health emergency to build a viable business.
So what’s the investment thesis?
Illumisoft is an unusual little company. It has a legacy commercial lighting business that provides some operating infrastructure and customer relationships. It has a UV-C air sanitation product that has undergone independent laboratory testing and received Canadian regulatory registration. It has a next-generation far-UVC platform under development with a major engineering partner. It has intellectual property, some recognizable investors and advisers, and a potentially meaningful institutional sales opportunity.
Those are real assets.
But it’s in that early mushy middle space where every potential client asks who else is using it, and everywhere it’s being used, it exists quietly, without drawing attention to itself.
The only one who sees that its working is the hospital administrator who sees infection numbers filling and costs doing likewise.
The company’s near-term investment case depends heavily on whether it can convert its proposed hospital programs into actual revenue.
Its longer-term upside depends on whether SaniLux breaks through and becomes a safe, effective, commercially viable product that customers can deploy at scale.
The next pandemic will arrive whether we’re prepared for it or not.
Illumisoft is betting that, before it does, enough hospitals, governments and building owners will decide that cleaning the air is no longer optional. It’s a reasonable bet on the direction of the world.
But if that takes a while, the ultimate sales push is inevitable, and will cost Illumisoft nothing.
It’ll be the next time there’s reports of an unknown lethal infection, or a terrible virus, or a communicable rash.
The next time we’re stuck indoors for a month, banging pots and pans on our balconies to thank overworked medical staff. UVC will be in the cat bird seat, ready to take orders.
And that’s exactly why it’s worth watching.
— Chris Parry
Disclosure: This article is based on Illumisoft’s October 2026 investor presentation, financial statements and MD&A for the six months ended June 30, 2026, and the University of Leeds laboratory report dated August 2022. Company forecasts, market estimates and planned deployments are not guaranteed outcomes. This is commentary, not investment advice. Illumisoft is an Equity Guru marketing client.
Get Today's Idea before the open.
Weekly. Free. Unsubscribe anytime.
A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.